Previous close | 125.21 |
Open | 125.59 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 125.59 - 127.64 |
52-week range | 68.37 - 142.93 |
Volume | |
Avg. volume | 22,405 |
Market cap | 2.874B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 0.42 |
EPS (TTM) | 3.03 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Earnings preview of key companies reporting next week and what to look out for.
Bagsværd, Denmark, 26 April 2024 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 32/2024 dated 24 April 2024, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 26 April 2024. Number of
Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?